BioSpace News Archive

The American Red Cross and the American Cancer Society announced their Give Blood to Give Time partnership to raise awareness on how blood donations help patients fighting cancer.

Feb. 10, 2020 14:30 UTC Experienced executive to lead corneal disease clinical program for TTHX1114 SAN DIEGO--( BUSINESS WIRE )-- Trefoil Therapeutics today announced the appointment of Thomas M. Tremblay, RN, BSN to the newly created position of Vice President, Clinical Development. He brings to Trefoil more than 25 years of experience in pharmaceutical development across a variety of therapeutic areas. This press release features multimedia. View the full release he

Infiniti Helped a Leading Medical Imaging Market Client Enhance Operational Efficiency and Reduce Downstream Costs by 22%

Further to my statement on February 9, 2020, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose a risk of significant harm to public health.

Embark announces preliminary research findings linking elevated levels of inbreeding to shorter lifespan in dogs; partners with breeders in commitment to improve long-term canine health

Bold Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has received clearance from Health Canada to initiate a Phase 1b trial of its first-in-class anti-resistance therapeutic, BOLD-100, in combination with FOLFOX for the treatment of gastric, pan

MiraMed Global Services, Inc. (MiraMed), a leader in healthcare business process outsourcing (BPO) solutions, is pleased to announce the successful completion of its SOC (System and Organization Controls) examination for its family of companies.

“I got tired of using products on the market that do not work very well and keep dying and losing memory,” said an inventor from Mitchell, Ind.

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab,

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced that the underwriters of the Company’s initial public offering